Piramal Enterprise to acquire Ind-Swift Laboratories’ facilities

04 Sep 2012 Evaluate

Piramal Enterprise is looking to acquire Ind-Swift Laboratories’ contract research and manufacturing business, for a deal which is estimated to the worth of around Rs 1,000-1,200 crore. This acquisition is expected to boost the contract research and manufacturing services (CRAMS) division of Piramal, namely, Pharma Solutions along with its API manufacturing business.

In a bid to diversify into various businesses, Piramal after selling its domestic formulation business to Abbott for Rs 17,600 crore in 2010 has invested into pharma, telecom and information management and financial services sectors.

Meanwhile, Ind-Swift, a north India based pharmaceutical company, is the flagship company of India based Ind Swift Group. Ind-Swift manufactures and markets finished dosage forms, through its different divisions, focusing on the needs of various therapeutic segments. The divisions include Super Speciality, Animal Division, Daignozis, Institutions, Agile, Bio Sciences, Ethical, Health Care, Max Care, Mega care, Neuro and Resurgence.

Piramal Enterprises Share Price

827.90 0.00 (0.00%)
18-May-2024 12:50 View Price Chart
Peers
Company Name CMP
Bajaj Finance 6740.00
Shriram Finance 2366.85
Aditya Birla Capital 223.45
SBI Cards AndPayment 714.50
Chola Invest & Fin. 1280.40
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.